Patients with advanced NSCLC harboring EGFR mutation are treated with EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib, as first‐line treatment leading to high response rates and prolonged progression‐free‐survival (PFS) [5]. Here, EGFR is linked to non-small cell lung carcinoma.